



BLA 761077/S-025

SUPPLEMENT APPROVAL

Amgen Inc.
Attention: Sharon Wu, MS, RAC
Manager, Regulatory Affairs
One Amgen Center Drive
Thousand Oaks, CA 91320-1799

Dear Sharon Wu:

Please refer to your supplemental biologics license application (sBLA) received December 19, 2024, and your amendments, submitted under section 351(a) of the Public Health Service Act for Aimovig (erenumab-aooe) injection.

This Prior Approval sBLA provides for updates to the autoinjector Instructions for Use (IFU), Reference Guide (RG), and secondary packaging for both the 70mg/mL and 140mg/mL strengths.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at FDA.gov,¹ that is identical to the enclosed labeling (text for the Instructions for Use) and include the labeling changes proposed in any pending “Changes Being Effectuated” (CBE) supplements.

Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in Microsoft Word format that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELING

Submit final printed carton labeling that is identical to the carton labeling submitted on June 9, 2025, and tray labeling that is identical to the tray labeling submitted on December 19, 2024, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved BLA 761077/S-025.**” Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, contact Lyal Tressler, Regulatory Project Manager, by email at lyal.tressler@fda.hhs.gov or by telephone at (240) 402-0434.

Sincerely,

{See appended electronic signature page}

Alice T.D. Hughes, MD
Deputy Director for Safety
Division of Neurology 2
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Instructions for Use (IFU), 70mg/mL and 140mg/mL
 - Reference Guide (RG), 70mg/mL and 140mg/mL

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

ALICE HUGHES
06/19/2025 01:08:48 AM